Biorithm

Executive Summary

Biorithm, a Singapore-based medtech startup spun off from Nanyang Technological University in 2020, is developing a digital health platform for remote maternal monitoring. Its flagship femom system integrates a clinical-grade fetal-maternal sensor, patient-reported data, and a clinician dashboard to enable continuous, data-driven obstetric care. The platform aims to address critical gaps in prenatal monitoring, particularly in underserved regions and high-risk pregnancies, by facilitating early detection of complications and reducing hospital visits. Currently in early clinical phase, Biorithm is positioned to tap into the growing digital maternal health market, driven by increasing awareness and healthcare digitization in Southeast Asia. The company benefits from strong academic backing and a focus on evidence-based clinical outcomes, though it has not yet disclosed funding amounts or valuation.

Upcoming Catalysts (preview)

• Q3 2026Completion of clinical validation study60% success
• Q4 2026Regulatory clearance from Health Sciences Authority (HSA) Singapore50% success
• H1 2027Strategic partnership with a major hospital chain in Southeast Asia40% success